Dual-target CAR-T cell therapy: latest updates from the 2025 ASH annual meeting - PubMed
3 hours ago
- #Hematological Malignancies
- #Immunotherapy
- #CAR-T Therapy
- Dual-target CAR-T cell therapy addresses limitations of single-target approaches, such as antigen heterogeneity and escape.
- Recent advancements include diverse receptor architectures, logic-gated designs, and novel manufacturing platforms.
- Preclinical data show improved disease control in B-cell malignancies, acute myeloid leukemia, and autoimmune diseases.
- Clinical trials and preclinical investigations of dual-target CAR-T were highlighted at the 2025 ASH annual meeting.
- Key studies target combinations like CD79b/CD19 for B-cell lymphoma and CD123/CLL1 for AML to reduce off-target effects.